Orexin Receptor Antagonists for Insomnia: What 77 Clinical Trials Show About Dayvigo, Belsomra & Quviviq

Quick Summary

• Dual Orexin Receptor Antagonists (DORAs) add roughly 19 to 31 minutes of sleep per night compared to a placebo.

• DORAs shorten both the time it takes to fall asleep and the total time spent awake in the middle of the night.

• DORAs did not reliably improve how well people rated their sleep, although people with insomnia disorder and people in longer trials saw a small benefit.

• DORAs are generally well tolerated, but they raise the risk of next-day sleepiness and unusual sleep experiences such as vivid dreams.

Dual Orexin Receptor Antagonists: The New Sleeping Pill

It is probably no surprise that chronic sleep problems can affect nearly every part of your health and daily life. Sleeping pills are the second-line recommendation for treating insomnia and for decades, the standard medications for sleep problems have been benzodiazepines and “Z-drugs”.

These standard, older medications sedate the brain, but they come with well-known downsides. Downsides can include problems with thinking and memory, poorer driving, falls, and the potential for dependence (De Crescenzo et al., 2022; Gunja, 2013). Because of these risks, researchers have spent years looking for ways to help people sleep without simply turning down the whole brain and nervous system.

Recently a newer class of sleep medications known as Dual Orexin Receptor Antagonists (DORAs) has emerged as a popular alternative. Rather than acting as a heavy sedative, DORAs target a completely different chemical pathway in the brain.

But how well do DORAs actually work, and what are the trade-offs? A recent study by Stefanou et al. (2026) pooled 77 clinical trials to find out how effective and safe these medications are for people struggling with their sleep.

So, what exactly are these medications, and how do they change the way the brain operates at night?

What Are Dual Orexin Receptor Antagonists (DORAs)?

DORAs are a modern class of prescription sleep medications that work by temporarily blocking the brain’s wake-promoting signals, allowing natural sleep to take over. To understand how DORAs function, it helps to look at the specific brain chemicals they target.

During the day, a region of your brain called the lateral hypothalamus produces chemicals known as orexins. Orexins A and B are neurotransmitters, chemical messengers in the brain, that are mainly responsible for keeping you awake and alert.

You can think of the orexin system as your brain’s internal wakefulness stabiliser. When this system is active, it sends signals to two receptors (orexin receptor 1 and orexin receptor 2) that keep you awake, attentive, and engaged with the world around you. In some people with chronic sleep problems, such as insomnia, this wakefulness system is thought to stay too active at night, making it hard to wind down.

Older sleep medications work by boosting a different chemical called GABA, which acts like a heavy brake pedal that slows down brain activity across the board. DORAs take a completely different approach.

Instead of pressing the brake, Dual Orexin Receptor Antagonists take the foot off the gas.

By attaching to the orexin receptors, DORAs stop the wake-promoting chemicals from doing their job. Blocking the “stay awake” signal leaves room for your body’s natural sleep drive to take over.

Three DORAs are currently approved in various parts of the world: suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq).

So, we understand how DORAs are supposed to work in the brain, but how are these medications tested in scientific research?

How Did Researchers Measure the Effectiveness of DORAs In This Study?

Stefanou et al. (2026) evaluated the DORAs by combining data from many clinical trials, looking at both how patients feel they slept and what objective monitoring devices record. Stefanou et al. (2026) carried out a systematic review and meta-analysis, a statistical method that combines the results of many independent studies to find the overall trend.

The analysis was large. The researchers gathered data from 77 randomized controlled trials, studies where people are randomly assigned to the drug or a placebo (a dummy pill), involving 16,416 participants.

Stefanou et al. (2026) also included people with a wide range of conditions, such as major depressive disorder, Alzheimer’s disease, obstructive sleep apnea, and Parkinson’s disease, as well as 24 studies of healthy volunteers. Even so, most of the data on sleep time and sleep quality came from studies of people with insomnia disorder, so the results speak most clearly to that group.

To get a complete picture, the researchers looked at two types of data. The first was subjective data, information reported directly by patients in daily sleep diaries. The second was objective data from polysomnography, an overnight test that records brain waves, breathing, oxygen levels, and heart rate, or from actigraphy, a wearable device that tracks movement to estimate sleep.

Note that almost all of the trials behind the main results were funded by drug companies. However, we’ll note what the independent studies showed as well, below.

With this large pool of data covering both how people felt and what the machines recorded, what is the actual impact on the total amount of sleep someone gets?

How Much Extra Sleep Do DORAs Actually Provide?

On average, people taking a DORA gain between 19 and 31 extra minutes of sleep per night compared to those taking a placebo. This increase in total sleep time was one of the most consistent benefits across the trials analyzed by Stefanou et al. (2026).

In their morning sleep diaries, people taking a DORA estimated that they slept about 19 minutes longer than those in the placebo group.

The objective data told an even stronger story. When sleep was measured by polysomnography or actigraphy, people on the medication slept an average of 31 minutes longer. That is roughly the length of a TV episode, added back to the night.

When the researchers set aside the drug company-funded studies, the three small independent trials that remained still showed about 22 extra minutes of objectively measured sleep (Stefanou et al., 2026).

Although it may seem strange that there was a gap between subjective (what people perceived) and objective (machine recorded) results, this is actually common in sleep research.

People with insomnia often experience sleep state misperception, where they feel they have been awake for longer than they actually have. That may explain part of the difference here, although the diary and device results also came from partly different sets of trials.

The trials varied in how large a benefit they found, but almost all of them pointed in the same direction. Whichever way sleep was measured, blocking the brain’s wakefulness signal led to longer sleep.

Adding 20 to 30 minutes of sleep is a positive outcome if you have insomnia, but does this medication help with the frustrating process of falling asleep in the first place?

Do DORAs Help You Fall Asleep Faster?

Yes, DORAs reduce the time it takes to fall asleep by about 8 to 10 minutes. For many people, lying in bed staring at the ceiling while waiting for sleep is the most distressing part of the night.

In sleep science, the time it takes to fall asleep is called sleep onset latency. Stefanou et al. (2026) found that people taking a DORA reported in their sleep diaries that they fell asleep about 8 minutes faster than those taking a placebo. Once again, the objective devices recorded a slightly larger benefit, at nearly 10 minutes faster.

Eight to 10 minutes might not sound like a big shift, but it can change how bedtime feels. When you are struggling with insomnia, worrying about not falling asleep can keep you awake even longer. Getting to sleep a little sooner may take some of the edge off that bedtime frustration.

Getting to sleep slightly faster is helpful, but what happens if you are someone who keeps waking up at 3:00 AM?

Can DORAs Prevent Middle-of-the-Night Waking?

DORAs do not stop night wakings, but they reduce the total time spent awake during the night, by about 7 to 19 minutes. Waking in the middle of the night and struggling to get back to sleep is a classic sign of sleep maintenance insomnia, the type of insomnia where staying asleep is the main problem.

Researchers measure this problem with Wake After Sleep Onset (WASO), the total number of minutes a person spends awake between first falling asleep and getting up for the day. Stefanou et al. (2026) found that people taking DORAs reported about 7 fewer minutes awake in the middle of the night.

The objective sleep trackers showed a bigger reduction, recording nearly 19 fewer minutes of wakefulness.

Interestingly, the number of times people woke up during the night did not change. People taking DORAs still woke up about as often as the placebo group; they simply spent less time awake overall. This pattern suggests they got back to sleep more quickly.

Stefanou et al. (2026) did not test why. One possible explanation is that with the orexin system still dampened, a brief awakening is less likely to turn into full alertness.

If you are someone who wakes at 3 a.m., a DORA is unlikely to stop that waking from happening. What it may do is shorten the time you lie there waiting to drift off again.

If people are sleeping longer and spending less time awake in the dark, do they feel like their sleep is more restorative?

Does Taking a DORA Improve Overall Sleep Quality?

No, overall sleep quality did not clearly improve for the average person taking a DORA, though some groups saw a small benefit.

You might assume that sleeping 20 to 30 minutes longer and falling asleep faster would automatically translate into feeling like you slept well, but the research paints a more complicated picture.

Stefanou et al. (2026) analyzed 17 studies that asked patients to rate their sleep quality using questionnaires such as the Pittsburgh Sleep Quality Index. Across all participants and conditions, there was no statistically significant difference, meaning no difference larger than chance could explain, in sleep quality between DORAs and placebo.

The review also found no difference in daytime functioning scores, such as how tired or impaired people felt during the day (Stefanou et al., 2026).

When the researchers looked at smaller groups within the data, a few differences emerged.

• People diagnosed with insomnia disorder reported a small but clear improvement in sleep quality.

• Trials lasting longer than six weeks also showed a small improvement. This longer-trial result suggests that while the amount of sleep improves within the first few weeks, it may take longer for a person’s sense of sleep quality to catch up.

If the improvements in sleep quality are small, what side effects do users need to weigh against these benefits?

What Are the Common Side Effects of DORAs?

The most frequently reported side effects of DORAs are next-day sleepiness and unusual sleep experiences, such as vivid dreams or nightmares. DORAs avoid some of the risks associated with older sedatives, but they have side effects of their own.

Because DORAs dampen the brain’s wakefulness system, that effect can sometimes linger into the next morning. Stefanou et al. (2026) found that people taking a DORA were nearly three times more likely than those on a placebo to report somnolence, daytime sleepiness that appears after starting treatment. It is possible that this lingering grogginess is one reason people did not rate their sleep quality much higher, although Stefanou et al. (2026) did not test that link.

The other notable side effect involves dreaming. People taking DORAs were 2.6 times more likely to report parasomnia symptoms, unusual experiences during sleep, which in these trials meant vivid or abnormal dreams, nightmares, or sleep paralysis (Stefanou et al., 2026).

Orexin helps regulate REM sleep, the stage when most dreaming happens, so blocking orexin may make dreams more intense. A separate review raised concern about narcolepsy-like symptoms with DORAs, narcolepsy being a disorder that causes overwhelming daytime sleepiness (Na et al., 2024). Two studies of reports sent to drug safety databases also linked DORAs with sleep paralysis, parasomnias and sleepiness (Jiang et al., 2024; Sun et al., 2026).

Despite these side effects, DORAs appear to be well tolerated overall. The number of people who dropped out of the trials because of side effects was about the same in the DORA and placebo groups (Stefanou et al., 2026).

So DORAs seem reasonably easy to live with, but do they keep working over months, and what happens when you stop taking them?

Do the Benefits Of Taking Dual Orexin Receptor Antagonists Last, and What Happens When You Stop?

The benefits of DORAs appear to last for at least a year, and stopping did not cause rebound insomnia in the trials that checked. Three trials followed people for six months or more, and all three found that the extra sleep held up (Fan et al., 2017; Kärppä et al., 2020; Michelson et al., 2014).

The longest was a one-year trial of suvorexant, in which people on the drug gained about 27 minutes more self-reported sleep than people on placebo (Michelson et al., 2014). The benefit was also no smaller in trials longer than six weeks than in shorter ones (Stefanou et al., 2026). The review’s authors suggest this pattern points to a lower risk of tolerance (needing more of a drug to get the same effect) and dependence.

What about stopping a DORA?

No rebound insomnia (sleep becoming worse than it was before treatment) or withdrawal symptoms were reported in three trials that monitored people for a short period after they stopped taking a DORA (Kärppä et al., 2020; Mignot et al., 2022; Uchimura et al., 2024). Because people were only monitored for a short period, Stefanou et al. (2026) caution that the real effect can only be confirmed by trials designed specifically to measure what happens when people stop after long-term use (for example, it is unclear whether baseline insomnia symptoms returned on stopping the pills).

Knowing that these medications offer specific benefits but come with certain side effects, what is the recommended way to address chronic sleep problems long-term?

Where To From Here?

If you are struggling with persistent sleep problems, treatment guidelines recommend cognitive behavioral therapy for insomnia (CBT-I) as the first treatment for chronic insomnia (Qaseem et al., 2016; Riemann et al., 2023). UK guidance recommends the DORA daridorexant when CBT-I has not worked or is not available (National Institute for Health and Care Excellence, 2023). Under that guidance, the drug is stopped if it has not helped enough within three months.

Why CBT-I first? Working with a behavioural sleep medicine specialist to address what is keeping your insomnia going involves a structured, individualized program that targets the specific behaviors, thoughts, and biological rhythms that keep your brain on high alert at night. Rather than relying on generic advice, a specialist will help you apply evidence-based techniques to rebuild your natural sleep drive, regulate your body clock, and reduce the hyperarousal (a state where the brain and body stay too switched on) that makes falling asleep feel impossible.

By addressing the causes of your sleep disruption directly, you can build a long-term approach to resolve the problem without medications and get the sleep you are looking for.

Frequently Asked Questions About Orexin Receptor Antagonists for Insomnia

Q1: What is a Dual Orexin Receptor Antagonist sleeping pill?

A1: A DORA (dual orexin receptor antagonist) is a prescription sleep medication that blocks orexin, the brain chemical that keeps you awake and alert. Rather than sedating the whole brain like older sleeping pills, a DORA turns down the “stay awake” signal so natural sleep can take over. The three DORAs currently approved are suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq).

Q2: How much extra sleep do Dual Orexin Receptor Antagonists give you?

A2: DORAs add about 19 minutes of sleep per night by people’s own estimates, and about 31 minutes when sleep is measured with monitoring devices, compared to a placebo (Stefanou et al., 2026). DORAs also help people fall asleep about 8 to 10 minutes faster and spend 7 to 19 fewer minutes awake during the night.

Q3: Do Dual Orexin Receptor Antagonists improve sleep quality?

A3:  DORAs did not clearly improve how people rated their sleep quality across all 17 studies that measured it (Stefanou et al., 2026). People with insomnia disorder, and people in trials lasting longer than six weeks, did report a small improvement.

Q4: What are the most common side effects of Dual Orexin Receptor Antagonists?

A4: The most common side effects of DORAs are next-day sleepiness and unusual sleep experiences such as vivid dreams, nightmares, or sleep paralysis. People taking a DORA were nearly three times more likely to report daytime sleepiness, and 2.6 times more likely to report these sleep experiences, than people taking a placebo (Stefanou et al., 2026). Even so, about the same number of people dropped out of the trials because of side effects in the DORA and placebo groups.

Q5: Can you get rebound insomnia when you stop a Dual Orexin Receptor Antagonist?

A5: Rebound insomnia and withdrawal symptoms were not found in three trials that monitored people for a short period after they stopped taking a DORA (Kärppä et al., 2020; Mignot et al., 2022; Uchimura et al., 2024). Stefanou et al. (2026) note that longer trials designed specifically to study stopping after long-term use are still needed to confirm this.

Q6: Should I try a Dual Orexin Receptor Antagonist or CBT-I first for insomnia?

A6: Treatment guidelines recommend cognitive behavioral therapy for insomnia (CBT-I) as the first treatment for chronic insomnia (Qaseem et al., 2016; Riemann et al., 2023). UK guidance recommends the DORA daridorexant when CBT-I has not worked or is not available (National Institute for Health and Care Excellence, 2023).

References

De Crescenzo, F., D’Alò, G. L., Ostinelli, E. G., Ciabattini, M., Di Franco, V., Watanabe, N., Kurtulmus, A., Tomlinson, A., Mitrova, Z., Foti, F., Del Giovane, C., Quested, D. J., Cowen, P. J., Barbui, C., Amato, L., Efthimiou, O., & Cipriani, A. (2022). Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: A systematic review and network meta-analysis. The Lancet, 400(10347), 170–184.

Fan, B., Kang, J., He, Y., Hao, M., Du, W., & Ma, S. (2017). Efficacy and safety of suvorexant for the treatment of primary insomnia among Chinese: A 6-month randomized double-blind controlled study. Neurology Asia, 22(1), 41–47.

Gunja, N. (2013). In the Zzz zone: The effects of Z-drugs on human performance and driving. Journal of Medical Toxicology, 9(2), 163–171.

Jiang, M., Li, H., & Kong, L. (2024). Data mining and safety analysis of dual orexin receptor antagonists (DORAs): A real-world pharmacovigilance study based on the FAERS database. Frontiers in Pharmacology, 15, 1436405.

Kärppä, M., Yardley, J., Pinner, K., Filippov, G., Zammit, G., Moline, M., Perdomo, C., Inoue, Y., Ishikawa, K., & Kubota, N. (2020). Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: Results from the phase 3 randomized clinical trial SUNRISE 2. Sleep, 43(9), zsaa123.

Michelson, D., Snyder, E., Paradis, E., Chengan-Liu, M., Snavely, D. B., Hutzelmann, J., Walsh, J. K., Krystal, A. D., Benca, R. M., Cohn, M., Lines, C., Roth, T., & Herring, W. J. (2014). Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: A phase 3 randomised, double-blind, placebo-controlled trial. The Lancet Neurology, 13(5), 461–471.

Mignot, E., Mayleben, D., Fietze, I., Leger, D., Zammit, G., Bassetti, C. L. A., Pain, S., Kinter, D. S., & Roth, T. (2022). Safety and efficacy of daridorexant in patients with insomnia disorder: Results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. The Lancet Neurology, 21(2), 125–139.

Na, H.-J., Jeon, N., Staatz, C. E., Han, N., & Baek, I.-H. (2024). Clinical safety and narcolepsy-like symptoms of dual orexin receptor antagonists in patients with insomnia: A systematic review and meta-analysis. Sleep, 47(2), zsad293.

National Institute for Health and Care Excellence. (2023). Daridorexant for treating long-term insomnia (Technology appraisal guidance TA922).

Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125–133.

Riemann, D., Espie, C. A., Altena, E., Arnardottir, E. S., Baglioni, C., Bassetti, C. L. A., Bastien, C., Berzina, N., Bjorvatn, B., Dikeos, D., Dolenc Groselj, L., Ellis, J. G., Garcia-Borreguero, D., Geoffroy, P. A., Gjerstad, M., Gonçalves, M., Hertenstein, E., Hoedlmoser, K., Hion, T., … Spiegelhalder, K. (2023). The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. Journal of Sleep Research, 32(6), e14035.

Stefanou, A., Lampropoulou, P., Papageorgiou, P., Boskou, I., Lappas, A. S., Christodoulou, N., Bozikas, V. P., & Samara, M. T. (2026). The effect of dual orexin receptor antagonists on sleep: A systematic review and pairwise meta-analysis. Sleep Medicine, 140, 108792.

Sun, Y., Xu, T., & Xu, H. (2026). Safety of dual orexin receptor antagonists: A real-world pharmacovigilance study. Expert Opinion on Drug Safety, 25(9), 1695–1701.

Uchimura, N., Taniguchi, M., Ariyoshi, Y., Oka, Y., Togo, O., & Uchiyama, M. (2024). Daridorexant in Japanese patients with insomnia disorder: A phase 3, randomized, double-blind, placebo-controlled study. Sleep Medicine, 122, 27–34.

Written By Dan Ford, DBSM, Sleep Psychologist

Published By The Better Sleep Clinic